ID   TE-15
AC   CVCL_1763
SY   TE15; Te15
DR   BTO; BTO:0004598
DR   CLO; CLO_0051370
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472042
DR   BioSample; SAMN10988301
DR   cancercelllines; CVCL_1763
DR   Cell_Model_Passport; SIDM00249
DR   CGH-DB; 317-1
DR   CGH-DB; 9266-4
DR   ChEMBL-Cells; CHEMBL3308221
DR   ChEMBL-Targets; CHEMBL2366086
DR   Cosmic; 753614
DR   Cosmic; 923183
DR   Cosmic; 983724
DR   Cosmic; 1043237
DR   Cosmic; 1123332
DR   Cosmic; 1612900
DR   Cosmic; 2698429
DR   Cosmic-CLP; 753614
DR   DepMap; ACH-000353
DR   EGA; EGAS00001000978
DR   GDSC; 753614
DR   GEO; GSM887694
DR   GEO; GSM888787
DR   GEO; GSM1670532
DR   IARC_TP53; 6332
DR   LiGeA; CCLE_057
DR   LINCS_LDP; LCL-1568
DR   PharmacoDB; TE15_1580_2019
DR   PRIDE; PXD002486
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1763
DR   PubChem_Cell_line; CVCL_1763
DR   RCB; RCB1951
DR   TKG; TKG 0266
DR   Wikidata; Q54972013
RX   PubMed=8509434;
RX   PubMed=9096669;
RX   PubMed=9290701;
RX   PubMed=15172977;
RX   PubMed=17804709;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=25984343;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 37 hours (PubMed=25984343).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-1G>A; ClinVar=VCV000634769; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=9096669).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=83.86%; East Asian, South=15.31%; South Asian=0.83%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Esophagus; UBERON=UBERON_0001043.
ST   Source(s): Cosmic-CLP; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 9
ST   D5S818: 9
ST   D7S820: 11
ST   TH01: 7
ST   TPOX: 9
ST   vWA: 15,18
DI   NCIt; C4024; Esophageal squamous cell carcinoma
DI   ORDO; Orphanet_99977; Squamous cell carcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 37
//
RX   PubMed=8509434; DOI=10.1007/BF01215923;
RA   Nishihira T., Hashimoto Y., Katayama M., Mori S., Kuroki T.;
RT   "Molecular and cellular features of esophageal cancer cells.";
RL   J. Cancer Res. Clin. Oncol. 119:441-449(1993).
//
RX   PubMed=9096669; DOI=10.1002/(SICI)1097-0215(19970328)71:1<79::AID-IJC14>3.0.CO;2-4;
RA   Barnas C., Martel-Planche G., Furukawa Y., Hollstein M., Montesano R.,
RA   Hainaut P.;
RT   "Inactivation of the p53 protein in cell lines derived from human
RT   esophageal cancers.";
RL   Int. J. Cancer 71:79-87(1997).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=15172977; DOI=10.1158/0008-5472.CAN-04-0172;
RA   Sonoda I., Imoto I., Inoue J., Shibata T., Shimada Y., Chin K.,
RA   Imamura M., Amagasa T., Gray J.W., Hirohashi S., Inazawa J.;
RT   "Frequent silencing of low density lipoprotein receptor-related
RT   protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in
RT   esophageal squamous cell carcinoma.";
RL   Cancer Res. 64:3741-3747(2004).
//
RX   PubMed=17804709; DOI=10.1158/0008-5472.CAN-07-2064;
RA   Boonstra J.J., van der Velden A.W., Beerens E.C.W., van Marion R.,
RA   Morita-Fujimura Y., Matsui Y., Nishihira T., Tselepis C., Hainaut P.,
RA   Lowe A.W., Beverloo H.B., van Dekken H., Tilanus H.W., Dinjens W.N.M.;
RT   "Mistaken identity of widely used esophageal adenocarcinoma cell line
RT   TE-7.";
RL   Cancer Res. 67:7996-8001(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//